Top news of 2025: Drugmakers invest in US capacities, agree to lower Medicaid prices; Pfizer buys obesity-focused biotech Metsera

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

NCGC00024928-23

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 12 USDMF, 5 CEP/COS, 4 JDMF, 4 KDMF, 11 NDC API, 22 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

76 Drugs in Development

76 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

132 FDF Dossiers, 26 FDA Orange Book, 56 Europe, 6 Canada, 14 Australia, 10 South Africa, 20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - EQ 20MG BASE/10ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 7 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 5 Actylis, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 24 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 2 Finar, 7 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 24 Kerry, 4 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 28 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Silverline Chemicals, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

73 Fillers, Diluents & Binders, 47 Coating Systems & Additives, 37 Direct Compression, 31 Granulation, 29 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 22 Controlled & Modified Release, 22 Taste Masking, 19 Chewable & Orodispersible Aids, 19 Film Formers & Plasticizers, 18 Solubilizers, 15 Topical, 15 Parenteral, 14 Co-Processed Excipients, 13 Lubricants & Glidants, 10 Rheology Modifiers, 5 Emulsifying Agents, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 26 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 33 Regulatory FDF Prices

MARKET PLACE

6 APIs, 9 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
30/12/2025	Chemische Fabrik Berg	Germany	Aging Life Science Co., Ltd.	20200623-209-J-492(2)	Tamoxifen citrate	2020-08-05	Chemische Fabrik Berg GmbH@Benechim SPRL	Germany	Mainthalstraβe 3, 06749 Bitterfeld-Wolfen, Germany@Rue Rene Magritte 163 Lessines 7860 Belgium
30/12/2025	Fareva	Luxembourg	Samoh Pharmaceutical Co., Ltd.	20210614-209-J-893	Tamoxifen citrate	2021-06-14	Excella GmbH & Co. KG	Germany	Nürnberger Str. 12, 90537 Feucht, Germany

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

NCGC00024928-23

NCGC00024928-23

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

40 API Suppliers

12 USDMF

5 CEP/COS

4 JDMF

4 KDMF

11 NDC API

22 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

76 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

132 FDF Dossiers

26 FDA Orange Book

56 Europe

6 Canada

14 Australia

10 South Africa

20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;ORAL - EQ 20MG BASE/10ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

7 DKSH

4 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

5 Actylis

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

24 BASF

1 Bioplus Life Sciences

1 Clariant

10 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

2 Finar

7 Gangwal Chemicals

4 Ideal Cures

4 Ingredion Pharma Solutions

24 Kerry

4 Keval Exports

4 Kima Chemical

6 Lonza Capsugel

17 Microlex e.U

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

28 Roquette

7 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

9 Sigachi Industries

3 Silverline Chemicals

3 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

TABLET;ORAL - EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 20MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons